[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643658":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":47,"centralContacts":51,"locations":59,"responsibleParty":72,"collaborators":11,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":11,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":11,"studyType":88,"phases":89,"briefSummary":91,"conditions":92,"keywords":11,"overallStatus":62,"whyStopped":11,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"Ono Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,19,22,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Single-dose ONO-3310","EXPERIMENTAL",null,[13],"Drug: ONO-3310",{"label":15,"type":16,"description":11,"interventionNames":17},"Single-dose placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo",{"label":20,"type":10,"description":11,"interventionNames":21},"Multiple-dose ONO-3310",[13],{"label":23,"type":16,"description":11,"interventionNames":24},"Multiple-dose placebo",[18],{"label":26,"type":10,"description":11,"interventionNames":27},"Single- and multiple-dose ONO-3310",[13],[29,34,38,41,44],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","ONO-3310","Single oral dose of ONO-3310 to HV",[9],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":11},"Placebo","Single oral dose of Placebo to HV",[15],{"type":30,"name":31,"description":39,"armGroupLabels":40,"otherNames":11},"Multiple oral dose of ONO-3310 to HV",[20],{"type":30,"name":35,"description":42,"armGroupLabels":43,"otherNames":11},"Multiple oral dose of Placebo to HV",[23],{"type":30,"name":31,"description":45,"armGroupLabels":46,"otherNames":11},"Single or multiple oral dose of ONO-3310 to CKD patients",[26],[48],{"name":49,"affiliation":5,"role":50},"Project Leader","STUDY_DIRECTOR",[52,56],{"name":5,"role":53,"phone":54,"phoneExt":11,"email":55},"CONTACT","+18665877745","clinical_trial@ono-pharma.com",{"name":57,"role":53,"phone":58,"phoneExt":11,"email":55},"International Clinical Trial Support Desk","+17162141777",[60],{"facility":61,"status":62,"city":63,"state":63,"zip":11,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":71,"contacts":11},"Souseikai Hakata Clinic","RECRUITING","Fukuoka","Japan","JP",{"type":67,"coordinates":68},"Point",[69,70],130.41667,33.6,{"lat":70,"lon":69},{"type":73,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643658","phase-1-a-study-of-ono-3310-in-healthy-adult-male-subjects-and-chronic-kidney-disease-patients-with-type-2-diabetes-mellitus-100643658",false,"NCT07619157","A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus","A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\nHealthy adult part\n\n1. Japanese healthy adult male subjects\n2. Age at the time of informed consent: 18 to 45\n3. BMI (at screening): 18.5 kg\u002Fm2 to less than 25.0 kg\u002Fm\\^2\n\nChronic kidney disease patient part\n\n1. Chronic kidney disease patients with type 2 diabetes mellitus\n2. Age at the time of informed consent: 18 to less than 65\n3. UACR measured by 24-hour urine collection: 300 mg\u002Fg to less than 3500 mg\u002Fg\n\nExclusion Criteria:\n\nHealthy adult part\n\n1. Subjects who currently receive treatment for or have a history of any of the following diseases: respiratory system, cardiovascular system, psychiatric system, nervous system, gastrointestinal system, immune system, liver, kidney, hematopoietic function, or endocrine function.\n2. Presence or history of severe allergy to drugs or food\n3. Presence or history of drug or alcohol dependence\n\nChronic kidney disease patient part\n\n1. Current symptoms of severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, cardiac, endocrine, neurologic, or cerebral disease\n2. Patients with type 1 diabetes mellitus\n3. Patients with a history of dialysis treatment",true,"ALL","18 Years","64 Years",{"count":86,"type":87},120,"ESTIMATED","INTERVENTIONAL",[90],"PHASE1","To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus",[93,94],"Type2 Diabetes Mellitus","Chronic Kidney Disease","2026-06-04",{"date":97,"type":98},"2026-06-08","ACTUAL",{"date":100,"type":98},"2026-06-02",{"date":102,"type":87},"2027-11-30",{"name":5,"class":6},1]